FDA approves generic travoprost

The FDA has approved an abbreviated new drug application for travoprost ophthalmic solution 0.004%, Alembic Pharmaceuticals announced in a press release.
The solution is therapeutically equivalent to Travatan Ophthalmic Solution 0.004% (Alcon).
It is indicated for the treatment of open angle glaucoma or ocular hypertension.
 

Full Story →